{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:53Z","timestamp":1740126173055,"version":"3.37.3"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T00:00:00Z","timestamp":1490745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The Glivec International Patient Assistance Programme makes Glivec (Imatinib mesylate) available to Philadelphia chromosome\/<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content>1 positive patients with chronic myeloid leukaemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>) in Lower and Middle Income Countries (LMIC). We have established a large cohort of 211 <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients who are eligible for Imatinib, in Kathmandu, Nepal. Thirty\u2010one patients were lost to follow\u2010up. We report on 180 <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients with a median age of 38\u00a0years (range 9\u201381). Of these 180 patients, 162 underwent cytogenetic testing and 110 were investigated by reverse transcription polymerase chain reaction. One hundred and thirty\u2010nine of the 180 patients (77\u00b72%) had at least one optimal response. Taken together, our cohort has a 95% overall survival rate and 78% of the patients were still taking Glivec at a median time of 48\u00b78\u00a0months (range 3\u2013140\u00a0months). The number of patients who actually failed therapy, as defined by the LeukaemiaNet 2013 criteria, was 39 (21\u00b77%). While our cohort has some differences with those in North America or Europe, we have shown Glivec is effective in inducing an optimal response in our patients in Nepal and that it is possible to deliver a clinical service for <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients using tyrosine kinase inhibitors in resource\u2010poor settings.<\/jats:p>","DOI":"10.1111\/bjh.14645","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T18:27:13Z","timestamp":1490812033000},"page":"991-999","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treating Philadelphia chromosome\/<i>BCR\u2010ABL1<\/i> positive patients with Glivec (Imatinib mesylate): 10\u00a0years\u2019 experience at Patan Hospital, Nepal"],"prefix":"10.1111","volume":"177","author":[{"given":"Gyan K.","family":"Kayastha","sequence":"first","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Ranjitkar","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha","family":"Gurung","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj K.","family":"KC","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjit","family":"Karki","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshan","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj K.","family":"Thapa","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Rajbhandari","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buddhi","family":"Poudyal","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paras","family":"Acharya","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Roberts","sequence":"additional","affiliation":[{"name":"National Health Service Blood and Transplant and Radcliffe Department of Medicine John Radcliffe Hospital Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Hayes","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-2743","authenticated-orcid":false,"given":"Buddha","family":"Basnyat","sequence":"additional","affiliation":[{"name":"Patan Academy of Health Science Kathmandu Nepal"},{"name":"Patan Hospital Kathmandu Nepal"},{"name":"Oxford University Clinical Research Unit\u2010Nepal Centre for Tropical Medicine and Global Health University of Oxford Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"},{"name":"Department of Oncology Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"745","article-title":"Clinical significance of complete cytogenetic response (CCyR) and major molecular response (MMR) achieved with different treatment modalities used as frontline therapy in chronic myeloid leukemia (CML) chronic phase (CP)","volume":"118","author":"Alattar M.","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-191254"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-378919"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-161737"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_8_14_1","first-page":"8","article-title":"Patan hospital experience in treating Philadelphia chromosome\/BCR\u2010ABL1 positive chronic myeloid leukemia patients with Gleevec (Imatinib mesylate); the first generation specific tyrosine kinase inhibitor","volume":"10","author":"Kayastha G.K.","year":"2010","journal-title":"BMC Blood Disorders"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2897"},{"volume-title":"Our Mission in Action","year":"2017","author":"Max Foundation","key":"e_1_2_8_19_1"},{"key":"e_1_2_8_20_1","unstructured":"NCCN(2016)Clinical Practice Guidelines in Oncology (NCCN Guidelines) R Chronic Myelogenous Leukemia version 1.2016.https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V112.11.186.186","article-title":"International Randomized Study of interferon versus STI571 (IRIS) 7\u2010year follow\u2010up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM)","volume":"112","author":"O'Brien S.G.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_22_1","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini E.","year":"2010","journal-title":"Pathologica"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_8_25_1","first-page":"32","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Vardiman J.W.","year":"2008"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:06:06Z","timestamp":1694538366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/bjh.14645"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14645","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2017,3,29]]},"assertion":[{"value":"2017-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}